Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in FARN?
Faron Pharmaceuticals Ltd: THE INVESTMENT CASE

Faron Pharma boss “excited” to begin first in-human trial of Clevegen later this year

A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
immunotherapy graphic
Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system

Faron Pharmaceuticals Ltd (LON:FARN) boss Markku Jalkanen has told investors he is “excited” to kick off the first in-human trial of his firm’s Clevegen cancer candidate later this year.

Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system.

READ: Faron welcomes latest Clever-1 data

The technology focuses on Clever-1, a surface cell receptor involved in cancer growth and spread. The changes anti-Clever-1 antibodies such as Clevegen induce allow immune cells to attack and kill cancer cells.

“We have continued to make good progress with our Clevegen programme and are very excited to start the first human clinical trial later this year,” said Markku Jalkanen.

“Our focus for the remainder of 2018 will be to continue to rapidly progress Clevegen through the clinic whilst also continuing to preserve cash in order to deliver value to shareholders.”

The focus on oncology followed disappointing Phase III top-line data from its lead drug, Traumakine for the condition called acute respiratory distress.

READ: Here's how Clevegen works 

Faron is still analysing the full dataset from that trial, while further data from separate studies are due over the coming months.

“Whilst we were disappointed with the results from the INTEREST study, we have made, and are continuing to make, efforts to fully understand the data in order to define the next steps in the Company's strategy for Traumakine,” added Jalkanen.

“The company will closely collaborate with the clinical community to complete this analysis and plan to provide full analysis of these findings in October.”

Plenty of cash

AIM-listed Faron had €11.2mln in the bank at the end of June (H1 17: €10.3mln), having raised just shy of €16mln in February.

It recorded an operating loss of €14.0mln for the opening six months of 2018 (H1 17: €6.8mln), although it has put in place a plan to help it reduce its cash burn going forward.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

September 12 2018

Related Articles

man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use